Dextenza in the Post-op Management of Vitreoretinal Surgeries

Inclusion Criteria:

• Men and women >18 years old

• Planning to undergo vitreoretinal surgery with the procedure type of pars planavitrectomy for either the indication of macular hole, epiretinal membrane removal,or vitreomacular traction.

Exclusion Criteria:

• Patients undergoing combined cataract or glaucoma procedure, intraocular lensexchange, scleral buckle, and/or implant of a drug delivery system

• History of complications, trauma, adverse events, disease in nasolacrimal region,including dacryocystitis, canaliculitis in either eye

• Structural lid abnormalities such as ectropion or entropion in surgical eye

• Ongoing use of systemic narcotic pain relievers

• Presence of any intraocular inflammation (cells and flare) in the study eye atscreening/baseline

• Pain score greater than "0" on the ocular pain assessment in the study eye atscreening/baseline

• Active or chronic or recurrent uncontrolled ocular or systemic inflammatory disease,including diabetes

• Other ocular surgeries or procedures during the study period and/or 6 months prior

• Intraoperative complications

• Patients with history of glaucoma (defined as glaucoma requiring 2 or more drops,IOP at baseline greater than 25, or advanced optic nerve cupping). Patients withglaucoma or ocular hypertension controlled with a single drop can be enrolled.

• Patients with a known hypersensitivity to NSAIDs or steroids or any component of thestudy medication.

• Have used ocular, topical, or systemic NSAIDs within 7 days prior to procedure andduring surgery.

• Use of intracameral or subconjunctival NSAIDs or steroids intraoperatively.

• Have used topical, ocular, inhaled or systemic steroids within 14 days prior toprocedure

• Are pregnant or nursing/lactating

• Participation as a subject in any clinical study within the 30 days prior torandomization.

• Surgeries using 20 gauge or 23 gauge instruments.